Cargando…
Breast Cancer Treatments: Updates and New Challenges
Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B, HER2 and triple-negative breast cancer (TNBC)) according to the expression of the estrogen receptor (ER) and the progesterone...
Autores principales: | Burguin, Anna, Diorio, Caroline, Durocher, Francine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399130/ https://www.ncbi.nlm.nih.gov/pubmed/34442452 http://dx.doi.org/10.3390/jpm11080808 |
Ejemplares similares
-
Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
por: Burguin, Anna, et al.
Publicado: (2020) -
Aminosteroid RM-581 Decreases Cell Proliferation of All Breast Cancer Molecular Subtypes, Alone and in Combination with Breast Cancer Treatments
por: Burguin, Anna, et al.
Publicado: (2023) -
Association of Breast Tumour Expression of Cannabinoid Receptors CBR1 and CBR2 with Prognostic Factors and Survival in Breast Cancer Patients
por: Morin-Buote, Jessica, et al.
Publicado: (2021) -
The Importance of Breast Adipose Tissue in Breast Cancer
por: Kothari, Charu, et al.
Publicado: (2020) -
Secreted Frizzled-Related Protein 1 as a Biomarker against Incomplete Age-Related Lobular Involution and Microcalcifications’ Development
por: Clemenceau, Alisson, et al.
Publicado: (2020)